Media coverage about BioLineRx (NASDAQ:BLRX) has trended positive on Monday, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. BioLineRx earned a daily sentiment score of 0.27 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 45.669449502977 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
BioLineRx (NASDAQ:BLRX) traded up 0.86% during trading on Monday, reaching $1.17. The company’s stock had a trading volume of 244,579 shares. The company’s market cap is $111.87 million. The stock has a 50-day moving average price of $1.12 and a 200 day moving average price of $0.97. BioLineRx has a 52-week low of $0.80 and a 52-week high of $1.38.
BioLineRx (NASDAQ:BLRX) last posted its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.05). On average, analysts expect that BioLineRx will post ($0.24) EPS for the current year.
Several analysts have recently issued reports on BLRX shares. Maxim Group set a $3.00 target price on BioLineRx and gave the stock a “buy” rating in a report on Monday, July 10th. Oppenheimer Holdings, Inc. started coverage on BioLineRx in a research note on Friday, August 4th. They issued an “outperform” rating and a $3.00 price objective on the stock. ValuEngine raised BioLineRx from a “sell” rating to a “hold” rating in a research note on Monday, July 17th. Roth Capital started coverage on BioLineRx in a research note on Thursday, August 3rd. They issued a “buy” rating and a $3.00 price objective on the stock. Finally, Zacks Investment Research raised BioLineRx from a “sell” rating to a “hold” rating in a research note on Wednesday, July 26th. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. BioLineRx presently has a consensus rating of “Buy” and a consensus target price of $2.88.
WARNING: This report was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another domain, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this report can be accessed at https://www.dispatchtribunal.com/2017/10/16/favorable-press-coverage-somewhat-unlikely-to-impact-bioline-rx-blrx-stock-price.html.
BioLineRx Company Profile
BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.
Receive News & Ratings for BioLineRx Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.